Biomedical papers, 2017 (vol. 161), issue 2

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017, 161(2):210-216 | 10.5507/bp.2017.008

Methylation status as a predictor of intravesical Bacillus Calmette-Guérin (BCG) immunotherapy response of high grade non-muscle invasive bladder tumor

Petr Huseka, Jaroslav Pacovskya, Marcela Chmelarovab, Miroslav Podholac, Milos Brodaka
a Department of Urology, Faculty of Medicine in Hradec Kralove, Charles University in Prague and University Hospital in Hradec Kralove, Czech Republic
b Institute of Clinical Biochemistry and Diagnostics, Faculty of Medicine in Hradec Kralove, Charles University in Prague and University Hospital in Hradec Kralove, Czech Republic
c The Fingerland Department of Pathology, Faculty of Medicine in Hradec Kralove, Charles University in Prague and University Hospital in Hradec Kralove, Czech Republic

Background and Aims: Genetic and epigenetic alterations play an important role in urothelial cancer pathogenesis. Deeper understanding of these processes could help us achieve better diagnosis and management of this life-threatening disease. The aim of this research was to evaluate the methylation status of selected tumor suppressor genes for predicting BCG response in patients with high grade non-muscle-invasive bladder tumor (NMIBC).

Materials and Methods: We retrospectively evaluated 82 patients with high grade non-muscle-invasive bladder tumor (stage Ta, T1, CIS) who had undergone BCG instillation therapy. We compared epigenetic methylation status in BCG-responsive and BCG-failure groups. We used the MS-MLPA (Methylation-Specific Multiplex Ligation-Dependent Probe Amplification probe sets ME001 and ME004. The control group was 13 specimens of normal urotel (bladder tissue)).

Results: Newly identified methylations in high grade NMIBC were found in MUS81a, NTRK1 and PCCA. The methylation status of CDKN2B (P=0.00312**) and MUS81a (P=0.0191*) is associated with clinical outcomes of BCG instillation therapy response. CDKN2B and MUS81a unmethylation was found in BCG failure patients.

Conclusion: The results show that the methylation status of selected tumor suppressor genes (TSGs) has the potential for predicting BCG response in patients with NMIBC high grade tumors. Tumor suppressor genes such as CDKN2b, MUS81a, PFM-1, MSH6 and THBS1 are very promising for future research.

Keywords: BCG, bladder cancer, CDKN2b, methylation

Received: June 27, 2016; Accepted: March 13, 2017; Prepublished online: March 22, 2017; Published: June 14, 2017


References

  1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2,Cancer Incidence and Mortality Worldwide: IARC CancerNase No. 10 2010, International Agency for Research on Cancer: Lyon, France.
  2. Jemal A, Murray T, Ward E , Samuels A, Tiwari RC, Ghafoor A. Cancer statistics 2005. CA Cancer J Clin 2005;55(1):10-30. Go to original source... Go to PubMed...
  3. Sylvester R, van der Meijden A, Witjes JA, Jakse G, Nomomura N, Cheng C. High grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 2005;66(6 Suppl):90-107. Go to original source... Go to PubMed...
  4. Lamm DL. Carcinoma in situ. Urol Clin North Am 1992;19(3):499-508. Go to PubMed...
  5. Burger M, Catto JW, Dalbangi G, Grossman HD, Herr H, Karakiewicz P. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013;63(2):234-41. Go to original source... Go to PubMed...
  6. Herr HW, Reuter VE. Progression of T1 bladder tumors. Cancer 1999;86(6):908-9. Go to original source... Go to PubMed...
  7. Chmelarova M, Krepinska E, Spacek J, LacoJ, Beranek M, Palicka V. Methylation in the p53 promoter in epithelial ovarian cancer. Clin Transl Oncol 2013;15(2):160-3. Go to original source... Go to PubMed...
  8. Chmelarova M, Krepinka E, Spacek J, Laco J, Nekvindova J, Palicka. Methylation analysis of tumour suppressor genes in ovarian cancer using MS-MLPA. Folia Biologica 2012,58(6):246-50. Go to PubMed...
  9. Pavicic W, Perkiö E, Kaur S, Peltomäki P. Altered methylation at microRNA-associated CpG islands in hereditary and sporadic carcinomas: a methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA)-based approach. Mol Med 2011;17(7-8):726-35. Go to original source... Go to PubMed...
  10. Dvorakova E, Chmelarova M, Laco Jan, Palicka V, Spacek J. Methylation analysis of tumor suppressor genes in endometroid carcinoma of endometrium using MS-MPLA. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2013;157(4):298-303. Go to original source... Go to PubMed...
  11. Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala H. An individual patient data meta-analysis of the long-term outcomes of ramdomised studies comparing intravecical mitomycin C versus bacillus Calmette-Guérin for non-muscle- invasive bladder cancer. Eur Urol 2009;56(2):247-56. Go to original source... Go to PubMed...
  12. Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006;67(6):1216-23. Go to original source... Go to PubMed...
  13. Shelley MD, Wilt TJ, Court J, Coles J, Kynaston H, Mason MD. Intravesical bacillus Calmette- Guérin is superior to mitomycin C in reducing tumour reccurence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004;93(4):485-90. Go to original source... Go to PubMed...
  14. Böhle A, Jocham D, Bock RP. Intravecical bacillus Calmette-Guérin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on reccurence and toxicity. J Urol 2003;169(1):90-5. Go to original source... Go to PubMed...
  15. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized trials. J Urol 2002;168:1964-70. Go to original source... Go to PubMed...
  16. Chang PF, Kwong J, Wang ZP, Tian J, Jiang L, Yang K. Intravesical bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database Syst Rev 2011;11(5).CD006885.
  17. Van der Meijden AP, Sylvester RJ, Oosterlick W, Hoeltl W, Bono AV. OERTC Genito-Urinary-Tract Cancer Group. Maintenance bacillus Calmette-Guérin for Ta, T1 bladder tumour is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 2003;44(4):429-34. Go to original source... Go to PubMed...
  18. Witjes JA, Paulo J, Soloway M, Lamm D, Kamat AM, Brausi M. Clinical practice recommedations for the prevention and management of intravesical therapy-associated adverse events. Eur Urol Suppl 2008;7(10):667-74. Go to original source...
  19. Zlotta AR, van Vooren, JP, Huygen K, Drowart A, Decock M, Pirson M. What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? Eur Urol 2000;37(4):470-7. Go to original source... Go to PubMed...
  20. Kulkarni GS, Hakenberg OW, Gschwend JE, Thalmann G, Kassouf W, Kamat A. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 2010;57(1):60-70. Go to original source... Go to PubMed...
  21. Cabello MJ, Grau L, Franco N, Orenes E, Alvarez M, Blanca A. Multiplex Methylation Profile of Tumor Suppressor Gene in Bladder Cancer. J Mol Diagn 2011;13(1):29-40. Go to original source... Go to PubMed...
  22. García-Baquero R, Puerta P, Betran M, Alvarez-Mújica M, Alvarez-Ossorio JL, Sánchez-Carbayo M. Methylation of tumor suppressor genes in a novel panel Predicts clinical outcomes in paraffin-embedded bladder tumors. Tumour Biol 2014;35(6):5777-86. Go to original source... Go to PubMed...
  23. Ibragimova I, Dulaimi E, Slifker JM, Chen DY, Uzzo RG, Cairns P. A global profile of gene promoter methylation in treatment-naive urothelial cancer. Epigenetics 2014;9(5):760-73. Go to original source... Go to PubMed...
  24. Salam C, Liang G, Tsai YC, Coulter J, Knowles MA, Feng AC. Progressive increase in de novo methylation of CpG islands in bladder cancer. Cancer Res 2000;60:2473-76. Go to PubMed...
  25. Chan MW, Chan LW, Tang NL, Tong JH, Lo KW, Lee TL. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 2002;8:464-70. Go to PubMed...
  26. Friedrich MG, Chandrasoma S, Siegmund KD, Weissenberger DJ, Cheng JC, Toma MI. Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur J Cancer 2005;41:2769-78. Go to original source... Go to PubMed...
  27. Dhawan D, Hamdy FC, Rehman I, Patterson J, Cross SS, Feeley KM. Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. J Pathol 2006;209:336-43. Go to original source... Go to PubMed...
  28. Yates DR, Rehman I, Abbod MF, Meuth M, Cross SS, Linkens DA. Promotor hypermethylation identifies prognostic risk in bladder cancer. Clin Cancer Res 2007;13:2046-53. Go to original source... Go to PubMed...
  29. Jarmalaite S, Jankevicius F, Kugonaite K, Suziedilis K, Mutanen P, Husgafvel-Pursiainen K. Promotor hypermethylation in tumor suppressor genes shows association with stage, grade and invasiveness of bladder cancer. Oncology 2008;75:145-51. Go to original source... Go to PubMed...
  30. Wolff EM, Chihara Y, Pan F, Weisenberger DJ, Siegmund KD, Sugano K. Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res 2010;70:8169-78. Go to original source... Go to PubMed...
  31. Agundez M, Grau L, Palou J, Algaba F, Villavicencio H, Sánchez-Carbayo M. Evaluation of the Methylation Status of Tumor Suppressor Genes for Predicting Bacillus Calmette-Guérin Response in Patients With T1G3 High-Risk Bladder Tumors. Eur Urol 2011;60:131-40. Go to original source... Go to PubMed...
  32. Alvarez-Múgica M, Fernandez-Gomez JM, Cebrian V, Fresno F, Escaf S, Sánchez-Carbayo M. Polyamine- modulated Factor-1 Methylation Predicts Bacillus Calmette-Guérin Response in Patients with High-grade Non-muscle-invasive Bladder Carcinoma. Eur Urol 2013;63:364-70. Go to original source... Go to PubMed...
  33. Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zochbaer-Müller S, Farinas AJ. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 2001;61:8656-63.
  34. López F, Sampedro T, Lorente JL, Domínguez F, Hermsen M, Suáres C. Utility of MS-MLPA in DNA methylation profiling in primary laryngeal squamous cell carcinoma. Oral Oncol 2014;50(4):291-7. Go to original source... Go to PubMed...
  35. Jiang D, Hong Q, Shen Y, Xu Y, Zhu H, Li Y. The diagnostic value of DNA methylation in leukemia: a systematic review and meta-analysis. PLoS One 2014;9(5):e96822. Go to original source... Go to PubMed...
  36. Ozdemir F, Altinisik J, Coksuer H, Buyru N. Methylation of tumor suppressor genes in ovarian cancer. Exp Ther Med 2012;4(6):1092-6. Go to PubMed...
  37. Xing M, Wang X, Palmai-Pallag T, Shen H, Helleday T, Hickson ID. Acute MUS81 depletion leads to replication fork slowing and a constitutive DNA damage response. Oncotarget 2015;6(35):37638-46. Go to original source... Go to PubMed...